From the Wires
Ventrix's VentriGel™ Demonstrates Potential to Prevent Heart Failure Following Heart Attack
Pre-clinical results showing safety and effectiveness published in Science Translational Medicine
By: PR Newswire
Feb. 20, 2013 02:01 PM
SAN DIEGO, Feb. 20, 2013 /PRNewswire/ -- Ventrix, Inc. announced today that its VentriGel™ cardiac repair scaffold safely and effectively mitigated left ventricular remodeling and improved cardiac function in pigs after myocardial infarction, or heart attack. The findings, made during pre-clinical studies, were published today in the journal Science Translational Medicine. Based on these and other results, Ventrix will initiate a first-in-man clinical trial for VentriGel later this year.
"These results give us strong validation that VentriGel has the potential to prevent the development of congestive heart failure in patients who are recovering from heart attack," said Adam Kinsey, Ph.D., CEO of Ventrix. "We will continue to develop VentriGel for this indication, for which there is a very acute need and large market potential."
As medical management and surgical tools have advanced, more and more patients are surviving heart attacks. However, damage to the heart during myocardial infarction can lead to a growth of dense scar tissue which cannot contribute to the pumping function of the heart. Over time, the heart wall will thin, and the heart fails, and the five-year survival rate for heart failure is only 50%. Currently, the only successful treatments for end-stage heart failure are total heart transplant and left ventricular assist devices.
In the study, the VentriGel scaffold was injected into pigs two weeks following heart attack via a minimally-invasive catheter. Three months after injection, more cardiac muscle and less scar tissue was found in the VentriGel-treated group compared to controls that did not receive VentriGel. This led to significant improvements in contractility and cardiac function and prevented heart failure in treated animals. Ejection fraction, one measure of cardiac function, was significantly greater after delivery of VentriGel compared to controls (74% versus 43%, p < 0.01). The global wall motion index, a measure of regional cardiac function, was significantly reduced (p < 0.05) by approximately 21% compared to controls, indicating an improvement in the contractility of the heart.
"After a myocardial infarction, patients who develop left ventricular dysfunction are at high risk for having another heart attack, and ultimately developing heart failure. These encouraging results suggest great therapeutic potential for VentriGel," said Dr. Anthony N. Demaria, former President of the American College of Cardiology, Professor of Medicine at the University of California, San Diego, and advisor to Ventrix.
About Myocardial Infarction
SOURCE Ventrix, Inc.
Latest AJAXWorld RIA Stories
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
SYS-CON Featured Whitepapers
Most Read This Week